Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Published in: Neurotherapeutics 4/2016

01-10-2016 | Review

Neuroimmune Response in Ischemic Preconditioning

Authors: Ashley McDonough, Jonathan R. Weinstein

Published in: Neurotherapeutics | Issue 4/2016

Login to get access

Abstract

Ischemic preconditioning (IPC) is a robust neuroprotective phenomenon in which a brief period of cerebral ischemia confers transient tolerance to subsequent ischemic challenge. Research on IPC has implicated cellular, molecular, and systemic elements of the immune response in this phenomenon. Potent molecular mediators of IPC include innate immune signaling pathways such as Toll-like receptors and type 1 interferons. Brain ischemia results in release of pro- and anti-inflammatory cytokines and chemokines that orchestrate the neuroinflammtory response, resolution of inflammation, and transition to neurological recovery and regeneration. Cellular mediators of IPC include microglia, the resident central nervous system immune cells, astrocytes, and neurons. All of these cell types engage in cross-talk with each other using a multitude of signaling pathways that modulate activation/suppression of each of the other cell types in response to ischemia. As the postischemic neuroimmune response evolves over time there is a shift in function toward provision of trophic support and neuroprotection. Peripheral immune cells infiltrate the central nervous system en masse after stroke and are largely detrimental, with a few subtypes having beneficial, protective effects, though the role of these immune cells in IPC is largely unknown. The role of neural progenitor cells in IPC-mediated neuroprotection is another active area of investigation as is the role of microglial proliferation in this setting. A mechanistic understanding of these molecular and cellular mediators of IPC may not only facilitate more effective direct application of IPC to specific clinical scenarios, but also, more broadly, reveal novel targets for therapeutic intervention in stroke.
Appendix
Available only for authorised users
Literature
1.
Gidday, J.M., Cerebral preconditioning and ischaemic tolerance. Nat Rev Neurosci, 2006. 7(6): p. 437–48.PubMedCrossRef
2.
Kariko, K., D. Weissman, and F.A. Welsh, Inhibition of toll-like receptor and cytokine signaling--a unifying theme in ischemic tolerance. J Cereb Blood Flow Metab, 2004. 24(11): p. 1288–304.PubMedCrossRef
3.
Zhang, J., Z.J. Yang, J.A. Klaus, et al., Delayed tolerance with repetitive transient focal ischemic preconditioning in the mouse. Stroke, 2008. 39(3): p. 967–74.PubMedPubMedCentralCrossRef
4.
Dirnagl, U., K. Becker, and A. Meisel, Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use. Lancet Neurol, 2009. 8(4): p. 398–412.PubMedPubMedCentralCrossRef
5.
Marsh, B., S.L. Stevens, A.E. Packard, et al., Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: a critical role for IRF3. J Neurosci, 2009. 29(31): p. 9839–49.PubMedPubMedCentralCrossRef
6.
Stenzel-Poore, M.P., S.L. Stevens, J.S. King, et al., Preconditioning reprograms the response to ischemic injury and primes the emergence of unique endogenous neuroprotective phenotypes: a speculative synthesis. Stroke, 2007. 38(2 Suppl): p. 680–5.PubMedCrossRef
7.
Moncayo, J., G.R. de Freitas, J. Bogousslavsky, et al., Do transient ischemic attacks have a neuroprotective effect? Neurology, 2000. 54(11): p. 2089–94.PubMedCrossRef
8.
Wegener, S., B. Gottschalk, V. Jovanovic, et al., Transient ischemic attacks before ischemic stroke: preconditioning the human brain? A multicenter magnetic resonance imaging study. Stroke, 2004. 35(3): p. 616–21.PubMedCrossRef
9.
10.
11.
12.
Pradillo, J.M., D. Fernandez-Lopez, I. Garcia-Yebenes, et al., Toll-like receptor 4 is involved in neuroprotection afforded by ischemic preconditioning. J Neurochem, 2009. 109(1): p. 287–94.PubMedCrossRef
13.
Stevens, S.L., P.Y. Leung, K.B. Vartanian, et al., Multiple preconditioning paradigms converge on interferon regulatory factor-dependent signaling to promote tolerance to ischemic brain injury. J Neurosci, 2011. 31(23): p. 8456–63.PubMedPubMedCentralCrossRef
14.
Stenzel-Poore, M.P., S.L. Stevens, and R.P. Simon, Genomics of preconditioning. Stroke, 2004. 35(11 Suppl 1): p. 2683–6.PubMedCrossRef
15.
Simon, R.P., R. Meller, A. Zhou, et al., Can genes modify stroke outcome and by what mechanisms? Stroke, 2012. 43(1): p. 286–91.PubMedCrossRef
16.
Marsh, B.J., S.L. Stevens, B. Hunter, et al., Inflammation and the emerging role of the toll-like receptor system in acute brain ischemia. Stroke, 2009. 40(3 Suppl): p. S34-7.PubMedCrossRef
17.
Stenzel-Poore, M.P., S.L. Stevens, Z. Xiong, et al., Effect of ischaemic preconditioning on genomic response to cerebral ischaemia: similarity to neuroprotective strategies in hibernation and hypoxia-tolerant states. Lancet, 2003. 362(9389): p. 1028–37.PubMedCrossRef
18.
Dave, K.R., I. Saul, R. Prado, et al., Remote organ ischemic preconditioning protect brain from ischemic damage following asphyxial cardiac arrest. Neurosci Lett, 2006. 404(1–2): p. 170–5.PubMedCrossRef
19.
Ren, C., X. Gao, G.K. Steinberg, et al., Limb remote-preconditioning protects against focal ischemia in rats and contradicts the dogma of therapeutic time windows for preconditioning. Neuroscience, 2008. 151(4): p. 1099–103.PubMedCrossRef
20.
Hausenloy, D.J., L. Candilio, and D.M. Yellon, Remote Ischemic Preconditioning and Cardiac Surgery. N Engl J Med, 2016. 374(5): p. 491–2.PubMed
21.
Meybohm, P., D. Hasenclever, and K. Zacharowski, Remote Ischemic Preconditioning and Cardiac Surgery. N Engl J Med, 2016. 374(5): p. 491.PubMed
22.
Healy, D.A., E. Boyle, D. McCartan, et al., A MultiCenter Pilot Randomized Controlled Trial of Remote Ischemic Preconditioning in Major Vascular Surgery. Vasc Endovascular Surg, 2015. 49(8): p. 220–7.PubMedCrossRef
23.
Gonzalez, N.R., M. Connolly, J.R. Dusick, et al., Phase I clinical trial for the feasibility and safety of remote ischemic conditioning for aneurysmal subarachnoid hemorrhage. Neurosurgery, 2014. 75(5): p. 590–8; discussion 598.PubMedPubMedCentralCrossRef
24.
Laiwalla, A.N., Y.C. Ooi, R. Liou, et al., Matched Cohort Analysis of the Effects of Limb Remote Ischemic Conditioning in Patients with Aneurysmal Subarachnoid Hemorrhage. Transl Stroke Res, 2016. 7(1): p. 42–8PubMedCrossRef
25.
Meller, R. and R.P. Simon, A critical review of mechanisms regulating remote preconditioning-induced brain protection. J Appl Physiol (1985), 2015. 119(10): p. 1135–42.CrossRef
26.
Barone, F.C., R.F. White, P.A. Spera, et al., Ischemic preconditioning and brain tolerance: temporal histological and functional outcomes, protein synthesis requirement, and interleukin-1 receptor antagonist and early gene expression. Stroke, 1998. 29(9): p. 1937–50; discussion 1950–1.PubMedCrossRef
27.
Kalakech, H., S. Tamareille, S. Pons, et al., Role of hypoxia inducible factor-1alpha in remote limb ischemic preconditioning. J Mol Cell Cardiol, 2013. 65: p. 98–104.PubMedCrossRef
28.
Hibert, P., D. Prunier-Mirebeau, O. Beseme, et al., Apolipoprotein a-I is a potential mediator of remote ischemic preconditioning. PLoS One, 2013. 8(10): p. e77211.PubMedPubMedCentralCrossRef
29.
Hibert, P., D. Prunier-Mirebeau, O. Beseme, et al., Modifications in rat plasma proteome after remote ischemic preconditioning (RIPC) stimulus: identification by a SELDI-TOF-MS approach. PLoS One, 2014. 9(1): p. e85669.PubMedPubMedCentralCrossRef
30.
Konstantinov, I.E., S. Arab, R.K. Kharbanda, et al., The remote ischemic preconditioning stimulus modifies inflammatory gene expression in humans. Physiol Genomics, 2004. 19(1): p. 143–50.PubMedCrossRef
31.
Wei, D., C. Ren, X. Chen, et al., The chronic protective effects of limb remote preconditioning and the underlying mechanisms involved in inflammatory factors in rat stroke. PLoS One, 2012. 7(2): p. e30892.PubMedPubMedCentralCrossRef
32.
Kirino, T., T. Nakagomi, H. Kanemitsu, et al., Ischemic tolerance. Adv Neurol, 1996. 71: p. 505–11.PubMed
33.
Gesuete, R., A.E. Packard, K.B. Vartanian, et al., Poly-ICLC preconditioning protects the blood–brain barrier against ischemic injury in vitro through type I interferon signaling. J Neurochem, 2012. 123 Suppl 2: p. 75–85.PubMedPubMedCentralCrossRef
34.
Leung, P.Y., S.L. Stevens, A.E. Packard, et al., Toll-like receptor 7 preconditioning induces robust neuroprotection against stroke by a novel type I interferon-mediated mechanism. Stroke J Cereb Circ, 2012. 43(5): p. 1383–9.CrossRef
35.
Packard, A.E., P.Y. Leung, K.B. Vartanian, et al., TLR9 bone marrow chimeric mice define a role for cerebral TNF in neuroprotection induced by CpG preconditioning. J Cereb Blood Flow Metab, 2012. 32(12): p. 2193–200.PubMedPubMedCentralCrossRef
36.
Stark, G.R., How cells respond to interferons revisited: from early history to current complexity. Cytokine Growth Factor Rev, 2007. 18(5–6): p. 419–23.PubMedPubMedCentralCrossRef
37.
Stark, G.R., I.M. Kerr, B.R. Williams, et al., How cells respond to interferons. Annu Rev Biochem, 1998. 67: p. 227–64.PubMedCrossRef
38.
Khorooshi, R. and T. Owens, Injury-induced type I IFN signaling regulates inflammatory responses in the central nervous system. J Immunol, 2010. 185(2): p. 1258–64.PubMedCrossRef
39.
Inacio, A.R., Y. Liu, B.H. Clausen, et al., Endogenous IFN-beta signaling exerts anti-inflammatory actions in experimentally induced focal cerebral ischemia. J Neuroinflammation, 2015. 12: p. 211.PubMedPubMedCentralCrossRef
40.
Shichita, T., T. Ago, M. Kamouchi, et al., Novel therapeutic strategies targeting innate immune responses and early inflammation after stroke. J Neurochem, 2012. 123 Suppl 2: p. 29–38.PubMedCrossRef
41.
Khorooshi, R., M.T. Morch, T.H. Holm, et al., Induction of endogenous Type I interferon within the central nervous system plays a protective role in experimental autoimmune encephalomyelitis. Acta Neuropathol, 2015. 130(1): p. 107–18.PubMedPubMedCentralCrossRef
42.
Blackburn, D., S. Sargsyan, P.N. Monk, et al., Astrocyte function and role in motor neuron disease: a future therapeutic target? Glia, 2009. 57(12): p. 1251–64.PubMedCrossRef
43.
Jha, M.K., W.H. Lee, and K. Suk, Functional polarization of neuroglia: Implications in neuroinflammation and neurological disorders. Biochem Pharmacol, 2015.
44.
Rama Rao, K.V. and T. Kielian, Neuron-astrocyte interactions in neurodegenerative diseases: Role of neuroinflammation. Clin Exp Neuroimmunol, 2015. 6(3): p. 245–263.PubMedPubMedCentralCrossRef
45.
Gliem, M., K. Krammes, L. Liaw, et al., Macrophage-derived osteopontin induces reactive astrocyte polarization and promotes re-establishment of the blood brain barrier after ischemic stroke. Glia, 2015. 63(12): p. 2198–207.PubMedCrossRef
46.
Ejlerskov, P., J.G. Hultberg, J. Wang, et al., Lack of Neuronal IFN-beta-IFNAR Causes Lewy Body- and Parkinson's Disease-like Dementia. Cell, 2015. 163(2): p. 324–39.PubMedPubMedCentralCrossRef
47.
Murphy, K., P. Travers, M. Walport, et al., Janeway’s immunobiology. 2012, New York: Garland Science.
48.
Marsh, B.J. and M.P. Stenzel-Poore, Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases. Curr Opin Pharmacol, 2008. 8(1): p. 8–13.
49.
50.
Lehnardt, S., E. Schott, T. Trimbuch, et al., A vicious cycle involving release of heat shock protein 60 from injured cells and activation of toll-like receptor 4 mediates neurodegeneration in the CNS. J Neurosci, 2008. 28(10): p. 2320–31.PubMedCrossRef
51.
Zhan, X., C. Kim, and F.R. Sharp, Very brief focal ischemia simulating transient ischemic attacks (TIAs) can injure brain and induce Hsp70 protein. Brain Res, 2008. 1234: p. 183–97.PubMedPubMedCentralCrossRef
52.
Venna, V.R., J. Li, S.E. Benashski, et al., Preconditioning induces sustained neuroprotection by downregulation of adenosine 5′-monophosphate-activated protein kinase. Neuroscience, 2012. 201: p. 280–7.PubMedCrossRef
53.
Bahjat, F.R., R.L. Williams-Karnesky, S.G. Kohama, et al., Proof of concept: pharmacological preconditioning with a Toll-like receptor agonist protects against cerebrovascular injury in a primate model of stroke. J Cereb Blood Flow Metab, 2011. 31(5): p. 1229–42.PubMedPubMedCentralCrossRef
54.
Makela, S.M., P. Osterlund, and I. Julkunen, TLR ligands induce synergistic interferon-beta and interferon-lambda1 gene expression in human monocyte-derived dendritic cells. Mol Immunol, 2011. 48(4): p. 505–15.PubMedCrossRef
55.
Malmgaard, L., Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res, 2004. 24(8): p. 439–54.PubMedCrossRef
56.
Caso, J.R., J.M. Pradillo, O. Hurtado, et al., Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation, 2007. 115(12): p. 1599–608.PubMedCrossRef
57.
Cao, C.X., Q.W. Yang, F.L. Lv, et al., Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficient mice. Biochem Biophys Res Commun, 2007. 353(2): p. 509–14.PubMedCrossRef
58.
Hayakawa, K., J. Qiu, and E.H. Lo, Biphasic actions of HMGB1 signaling in inflammation and recovery after stroke. Ann N Y Acad Sci, 2010. 1207: p. 50–7.PubMedPubMedCentralCrossRef
59.
Yu, S., T. Zhao, M. Guo, et al., Hypoxic preconditioning up-regulates glucose transport activity and glucose transporter (GLUT1 and GLUT3) gene expression after acute anoxic exposure in the cultured rat hippocampal neurons and astrocytes. Brain Res, 2008. 1211: p. 22–9.PubMedCrossRef
60.
Liu, M. and N.J. Alkayed, Hypoxic preconditioning and tolerance via hypoxia inducible factor (HIF) 1alpha-linked induction of P450 2C11 epoxygenase in astrocytes. J Cereb Blood Flow Metab, 2005. 25(8): p. 939–48.PubMedCrossRef
61.
62.
Weinstein, J.R., I.P. Koerner, and T. Moller, Microglia in ischemic brain injury. Futur Neurol, 2010. 5(2): p. 227–246.CrossRef
63.
64.
Trendelenburg, G. and U. Dirnagl, Neuroprotective role of astrocytes in cerebral ischemia: focus on ischemic preconditioning. Glia, 2005. 50(4): p. 307–20.PubMedCrossRef
65.
Norden, D.M., P.J. Trojanowski, E. Villanueva, et al., Sequential activation of microglia and astrocyte cytokine expression precedes increased iba-1 or GFAP immunoreactivity following systemic immune challenge. Glia, 2016. 64(2): p. 300–16.PubMedCrossRef
66.
Kaushal, V. and L.C. Schlichter, Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra. J Neurosci, 2008. 28(9): p. 2221–30.PubMedCrossRef
67.
Amantea, D., G. Micieli, C. Tassorelli, et al., Rational modulation of the innate immune system for neuroprotection in ischemic stroke. Front Neurosci, 2015. 9: p. 147.PubMedPubMedCentralCrossRef
68.
Rosenzweig, H.L., M. Minami, N.S. Lessov, et al., Endotoxin preconditioning protects against the cytotoxic effects of TNFalpha after stroke: a novel role for TNFalpha in LPS-ischemic tolerance. J Cereb Blood Flow Metab, 2007. 27(10): p. 1663–74.PubMedCrossRef
69.
Stevens, S.L., T.M. Ciesielski, B.J. Marsh, et al., Toll-like receptor 9: a new target of ischemic preconditioning in the brain. J Cereb Blood Flow Metab, 2008. 28(5): p. 1040–7.PubMedPubMedCentralCrossRef
70.
Gliem, M., A.K. Mausberg, J.I. Lee, et al., Macrophages prevent hemorrhagic infarct transformation in murine stroke models. Ann Neurol, 2012. 71(6): p. 743–52.PubMedCrossRef
71.
Macrez, R., C. Ali, O. Toutirais, et al., Stroke and the immune system: from pathophysiology to new therapeutic strategies. Lancet Neurol, 2011. 10(5): p. 471–80.PubMedCrossRef
72.
Dirnagl, U., Pathobiology of injury after stroke: the neurovascular unit and beyond. Ann N Y Acad Sci, 2012. 1268: p. 21–5.PubMedCrossRef
73.
Maki, T., K. Hayakawa, L.D. Pham, et al., Biphasic mechanisms of neurovascular unit injury and protection in CNS diseases. CNS Neurol Disord Drug Targets, 2013. 12(3): p. 302–15.PubMedPubMedCentralCrossRef
74.
Benarroch, E.E., Microglia: Multiple roles in surveillance, circuit shaping, and response to injury. Neurology, 2013. 81(12): p. 1079–88.PubMedCrossRef
75.
Michell-Robinson, M.A., H. Touil, L.M. Healy, et al., Roles of microglia in brain development, tissue maintenance and repair. Brain, 2015. 138(Pt 5): p. 1138–59.PubMedCrossRef
76.
Ginhoux, F., M. Greter, M. Leboeuf, et al., Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science, 2010. 330(6005): p. 841–5.PubMedPubMedCentralCrossRef
77.
Sedgwick, J.D., S. Schwender, H. Imrich, et al., Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc Natl Acad Sci U S A, 1991. 88(16): p. 7438–42.PubMedPubMedCentralCrossRef
78.
Butovsky, O., M.P. Jedrychowski, C.S. Moore, et al., Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. Nat Neurosci, 2014. 17(1): p. 131–43.PubMedCrossRef
79.
Garden, G.A. and T. Moller, Microglia biology in health and disease. J Neuroimmune Pharmacol, 2006. 1(2): p. 127–37.PubMedCrossRef
80.
Olson, J.K. and S.D. Miller, Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol, 2004. 173(6): p. 3916–24.PubMedCrossRef
81.
Lalancette-Hebert, M., G. Gowing, A. Simard, et al., Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J Neurosci, 2007. 27(10): p. 2596–605.PubMedCrossRef
82.
Nedergaard, M. and U. Dirnagl, Role of glial cells in cerebral ischemia. Glia, 2005. 50(4): p. 281–6.PubMedCrossRef
83.
84.
Cunningham, L.A., M. Wetzel, and G.A. Rosenberg, Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia, 2005. 50(4): p. 329–39.PubMedCrossRef
85.
Umekawa, T., A.M. Osman, W. Han, et al., Resident microglia, rather than blood-derived macrophages, contribute to the earlier and more pronounced inflammatory reaction in the immature compared with the adult hippocampus after hypoxia-ischemia. Glia, 2015. 63(12): p. 2220–30.PubMedPubMedCentralCrossRef
86.
Prinz, M., H. Schmidt, A. Mildner, et al., Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity, 2008. 28(5): p. 675–86.PubMedCrossRef
87.
Owens, T., R. Khorooshi, A. Wlodarczyk, et al., Interferons in the central nervous system: a few instruments play many tunes. Glia, 2014. 62(3): p. 339–55.PubMedCrossRef
88.
Costello, D.A. and M.A. Lynch, Toll-like receptor 3 activation modulates hippocampal network excitability, via glial production of interferon-beta. Hippocampus, 2013. 23(8): p. 696–707.PubMedCrossRef
89.
Tarassishin, L., H.S. Suh, and S.C. Lee, Interferon regulatory factor 3 plays an anti-inflammatory role in microglia by activating the PI3K/Akt pathway. J Neuroinflammation, 2011. 8: p. 187.PubMedPubMedCentralCrossRef
90.
Brendecke, S.M. and M. Prinz, How type I interferons shape myeloid cell function in CNS autoimmunity. J Leukoc Biol, 2012. 92(3): p. 479–88.PubMedCrossRef
91.
Teige, I., Y. Liu, and S. Issazadeh-Navikas, IFN-beta inhibits T cell activation capacity of central nervous system APCs. J Immunol, 2006. 177(6): p. 3542–53.PubMedCrossRef
92.
Kim, M.O., Q. Si, J.N. Zhou, et al., Interferon-beta activates multiple signaling cascades in primary human microglia. J Neurochem, 2002. 81(6): p. 1361–71.PubMedCrossRef
93.
Jin, S., J. Kawanokuchi, T. Mizuno, et al., Interferon-beta is neuroprotective against the toxicity induced by activated microglia. Brain Res, 2007. 1179: p. 140–6.PubMedCrossRef
94.
Kawanokuchi, J., T. Mizuno, H. Kato, et al., Effects of interferon-beta on microglial functions as inflammatory and antigen presenting cells in the central nervous system. Neuropharmacology, 2004. 46(5): p. 734–42.PubMedCrossRef
95.
Tanaka, T., K. Murakami, Y. Bando, et al., Interferon regulatory factor 7 participates in the M1-like microglial polarization switch. Glia, 2015. 63(4): p. 595–610.PubMedCrossRef
96.
Satoh, T., O. Takeuchi, A. Vandenbon, et al., The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol, 2010. 11(10): p. 936–44.PubMedCrossRef
97.
Salem, M., J.T. Mony, M. Lobner, et al., Interferon regulatory factor-7 modulates experimental autoimmune encephalomyelitis in mice. J Neuroinflammation, 2011. 8: p. 181.PubMedPubMedCentralCrossRef
98.
Chan, A., R. Seguin, T. Magnus, et al., Phagocytosis of apoptotic inflammatory cells by microglia and its therapeutic implications: termination of CNS autoimmune inflammation and modulation by interferon-beta. Glia, 2003. 43(3): p. 231–42.PubMedCrossRef
99.
Pang, Y., C.R. Chai, K. Gao, et al., Ischemia preconditioning protects astrocytes from ischemic injury through 14-3-3gamma. J Neurosci Res, 2015. 93(10): p. 1507–18.PubMedCrossRef
100.
Li, L., A. Lundkvist, D. Andersson, et al., Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab, 2008. 28(3): p. 468–81.PubMedCrossRef
101.
Hossain, M.Z., J. Peeling, G.R. Sutherland, et al., Ischemia-induced cellular redistribution of the astrocytic gap junctional protein connexin43 in rat brain. Brain Res, 1994. 652(2): p. 311–22.PubMedCrossRef
102.
Nakase, T., S. Fushiki, G. Sohl, et al., Neuroprotective role of astrocytic gap junctions in ischemic stroke. Cell Commun Adhes, 2003. 10(4–6): p. 413–7.PubMedCrossRef
103.
Chen, Y. and R.A. Swanson, Astrocytes and brain injury. J Cereb Blood Flow Metab, 2003. 23(2): p. 137–49.PubMedCrossRef
104.
Freitas-Andrade, M. and C.C. Naus, Astrocytes in neuroprotection and neurodegeneration: The role of connexin43 and pannexin1. Neuroscience, 2016. 323: p. 207–21.PubMedCrossRef
105.
Norden, D.M., A.M. Fenn, A. Dugan, et al., TGFbeta produced by IL-10 redirected astrocytes attenuates microglial activation. Glia, 2014. 62(6): p. 881–95.PubMedPubMedCentralCrossRef
106.
Gorina, R., M. Font-Nieves, L. Marquez-Kisinousky, et al., Astrocyte TLR4 activation induces a proinflammatory environment through the interplay between MyD88-dependent NFkappaB signaling, MAPK, and Jak1/Stat1 pathways. Glia, 2011. 59(2): p. 242–55.PubMedCrossRef
107.
Hung, C.C., C.H. Lin, H. Chang, et al., Astrocytic GAP43 Induced by the TLR4/NF-kappaB/STAT3 Axis Attenuates Astrogliosis-Mediated Microglial Activation and Neurotoxicity. J Neurosci, 2016. 36(6): p. 2027–43.PubMedCrossRef
108.
Pan, L.N., W. Zhu, Y. Li, et al., Astrocytic Toll-like receptor 3 is associated with ischemic preconditioning-induced protection against brain ischemia in rodents. PLoS One, 2014. 9(6): p. e99526.PubMedPubMedCentralCrossRef
109.
Lian, H., A. Litvinchuk, A.C. Chiang, et al., Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease. J Neurosci, 2016. 36(2): p. 577–89.PubMedPubMedCentralCrossRef
110.
Weinstein, J.R., Y. Quan, J.F. Hanson, et al., IgM-Dependent Phagocytosis in Microglia Is Mediated by Complement Receptor 3, Not Fcalpha/mu Receptor. J Immunol, 2015. 195(11): p. 5309–17.PubMedPubMedCentralCrossRef
111.
Hong, S., V.F. Beja-Glasser, B.M. Nfonoyim, et al., Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science, 2016.
112.
Benarroch, E.E., Neuron-astrocyte interactions: partnership for normal function and disease in the central nervous system. Mayo Clin Proc, 2005. 80(10): p. 1326–38.PubMedCrossRef
113.
Nakase, T. and C.C. Naus, Gap junctions and neurological disorders of the central nervous system. Biochim Biophys Acta, 2004. 1662(1–2): p. 149–58.PubMedCrossRef
114.
Wallraff, A., R. Kohling, U. Heinemann, et al., The impact of astrocytic gap junctional coupling on potassium buffering in the hippocampus. J Neurosci, 2006. 26(20): p. 5438–47.PubMedCrossRef
115.
Guitart, K., G. Loers, F. Buck, et al., Improvement of neuronal cell survival by astrocyte-derived exosomes under hypoxic and ischemic conditions depends on prion protein. Glia, 2016. 64(6): p. 896–910.PubMed
116.
Dodson, R.F., L.W. Chu, K.M. Welch, et al., Acute tissue response to cerebral ischemia in the gerbil. An ultrastructural study. J Neurol Sci, 1977. 33(1–2): p. 161–70.PubMedCrossRef
117.
del Zoppo, G.J., Inflammation and the neurovascular unit in the setting of focal cerebral ischemia. Neuroscience, 2009. 158(3): p. 972–82.PubMedCrossRef
118.
Rosenberg, G.A., E.Y. Estrada, and J.E. Dencoff, Matrix metalloproteinases and TIMPs are associated with blood–brain barrier opening after reperfusion in rat brain. Stroke, 1998. 29(10): p. 2189–95.PubMedCrossRef
119.
Filosa, J.A., H.W. Morrison, J.A. Iddings, et al., Beyond neurovascular coupling, role of astrocytes in the regulation of vascular tone. Neuroscience, 2016. 323: p. 96–109.PubMedCrossRef
120.
Hayakawa, K., T. Nakano, K. Irie, et al., Inhibition of reactive astrocytes with fluorocitrate retards neurovascular remodeling and recovery after focal cerebral ischemia in mice. J Cereb Blood Flow Metab, 2010. 30(4): p. 871–82.PubMedCrossRef
121.
Nawashiro, H., M. Brenner, S. Fukui, et al., High susceptibility to cerebral ischemia in GFAP-null mice. J Cereb Blood Flow Metab, 2000. 20(7): p. 1040–4.PubMedCrossRef
122.
Wang, X., K. Kang, S. Wang, et al., Focal cerebral ischemic tolerance and change in blood–brain barrier permeability after repetitive pure oxygen exposure preconditioning in a rodent model. J Neurosurg, 2016: p. 1–10.
123.
Jin, K., X.O. Mao, M.W. Eshoo, et al., cDNA microarray analysis of changes in gene expression induced by neuronal hypoxia in vitro. Neurochem Res, 2002. 27(10): p. 1105–12.PubMedCrossRef
124.
Shen, M., T.M. Piser, V.S. Seybold, et al., Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci, 1996. 16(14): p. 4322–34.PubMed
125.
Nagayama, T., A.D. Sinor, R.P. Simon, et al., Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci, 1999. 19(8): p. 2987–95.PubMed
126.
Bickler, P.E., J.P. Clark, P. Gabatto, et al., Hypoxic preconditioning and cell death from oxygen/glucose deprivation co-opt a subset of the unfolded protein response in hippocampal neurons. Neuroscience, 2015. 310: p. 306–21.PubMedCrossRef
127.
Cardona, A.E., E.P. Pioro, M.E. Sasse, et al., Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci, 2006. 9(7): p. 917–24.PubMedCrossRef
128.
Tang, Z., Y. Gan, Q. Liu, et al., CX3CR1 deficiency suppresses activation and neurotoxicity of microglia/macrophage in experimental ischemic stroke. J Neuroinflammation, 2014. 11: p. 26.PubMedPubMedCentralCrossRef
129.
Fumagalli, S., C. Perego, F. Ortolano, et al., CX3CR1 deficiency induces an early protective inflammatory environment in ischemic mice. Glia, 2013. 61(6): p. 827–42.PubMedCrossRef
130.
Helley, M.P., W. Abate, S.K. Jackson, et al., The expression of Toll-like receptor 4, 7 and co-receptors in neurochemical sub-populations of rat trigeminal ganglion sensory neurons. Neuroscience, 2015. 310: p. 686–98.PubMedCrossRef
131.
Lafon, M., F. Megret, M. Lafage, et al., The innate immune facet of brain: human neurons express TLR-3 and sense viral dsRNA. J Mol Neurosci, 2006. 29(3): p. 185–94.PubMedCrossRef
132.
Mishra, B.B., P.K. Mishra, and J.M. Teale, Expression and distribution of Toll-like receptors in the brain during murine neurocysticercosis. J Neuroimmunol, 2006. 181(1–2): p. 46–56.PubMedPubMedCentralCrossRef
133.
Wadachi, R. and K.M. Hargreaves, Trigeminal nociceptors express TLR-4 and CD14: a mechanism for pain due to infection. J Dent Res, 2006. 85(1): p. 49–53.PubMedPubMedCentralCrossRef
134.
Marlier, Q., S. Verteneuil, R. Vandenbosch, et al., Mechanisms and Functional Significance of Stroke-Induced Neurogenesis. Front Neurosci, 2015. 9: p. 458.PubMedPubMedCentralCrossRef
135.
Maysami, S., J.Q. Lan, M. Minami, et al., Proliferating progenitor cells: a required cellular element for induction of ischemic tolerance in the brain. J Cereb Blood Flow Metab, 2008. 28(6): p. 1104–13.PubMedCrossRef
136.
Naylor, M., K.K. Bowen, K.A. Sailor, et al., Preconditioning-induced ischemic tolerance stimulates growth factor expression and neurogenesis in adult rat hippocampus. Neurochem Int, 2005. 47(8): p. 565-72.PubMedCrossRef
137.
Nakagomi, T., S. Kubo, A. Nakano-Doi, et al., Brain vascular pericytes following ischemia have multipotential stem cell activity to differentiate into neural and vascular lineage cells. Stem Cells, 2015. 33(6): p. 1962–74.PubMedCrossRef
138.
Lang, B., H.L. Liu, R. Liu, et al., Astrocytes in injured adult rat spinal cord may acquire the potential of neural stem cells. Neuroscience, 2004. 128(4): p. 775–83.PubMedCrossRef
139.
Offner, H., S. Subramanian, S.M. Parker, et al., Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol, 2006. 176(11): p. 6523–31.PubMedCrossRef
140.
Vendrame, M., C. Gemma, K.R. Pennypacker, et al., Cord blood rescues stroke-induced changes in splenocyte phenotype and function. Exp Neurol, 2006. 199(1): p. 191–200.PubMedCrossRef
141.
Gelderblom, M., F. Leypoldt, K. Steinbach, et al., Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke, 2009. 40(5): p. 1849–57.PubMedCrossRef
142.
Ajmo, C.T., Jr., D.O. Vernon, L. Collier, et al., The spleen contributes to stroke-induced neurodegeneration. J Neurosci Res, 2008. 86(10): p. 2227–34.PubMedPubMedCentralCrossRef
143.
Das, M., C.C. Leonardo, S. Rangooni, et al., Lateral fluid percussion injury of the brain induces CCL20 inflammatory chemokine expression in rats. J Neuroinflammation, 2011. 8: p. 148.PubMedPubMedCentralCrossRef
144.
Jin, R., X. Zhu, L. Liu, et al., Simvastatin attenuates stroke-induced splenic atrophy and lung susceptibility to spontaneous bacterial infection in mice. Stroke, 2013. 44(4): p. 1135–43.PubMedPubMedCentralCrossRef
145.
Seifert, H.A., C.C. Leonardo, A.A. Hall, et al., The spleen contributes to stroke induced neurodegeneration through interferon gamma signaling. Metab Brain Dis, 2012. 27(2): p. 131–41.PubMedPubMedCentralCrossRef
146.
147.
148.
Shichita, T., Y. Sugiyama, H. Ooboshi, et al., Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med, 2009. 15(8): p. 946–50.PubMedCrossRef
149.
Swirski, F.K., M. Nahrendorf, M. Etzrodt, et al., Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science, 2009. 325(5940): p. 612–6.PubMedPubMedCentralCrossRef
150.
Gliem, M., D. Hermsen, N. van Rooijen, et al., Secondary intracerebral hemorrhage due to early initiation of oral anticoagulation after ischemic stroke: an experimental study in mice. Stroke, 2012. 43(12): p. 3352–7.PubMedCrossRef
151.
Huang, J., U.M. Upadhyay, and R.J. Tamargo, Inflammation in stroke and focal cerebral ischemia. Surg Neurol, 2006. 66(3): p. 232–45.PubMedCrossRef
152.
Su, W., S. Hopkins, N.K. Nesser, et al., The p53 transcription factor modulates microglia behavior through microRNA-dependent regulation of c-Maf. J Immunol, 2014. 192(1): p. 358–66.PubMedCrossRef
153.
Gliem, M., M. Schwaninger, and S. Jander, Protective features of peripheral monocytes/macrophages in stroke. Biochim Biophys Acta, 2016. 1862(3): p. 329–38.PubMedCrossRef
Metadata
Title
Neuroimmune Response in Ischemic Preconditioning
Authors
Ashley McDonough
Jonathan R. Weinstein
Publication date
01-10-2016
Publisher
Springer US
Published in
Neurotherapeutics / Issue 4/2016
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-016-0465-z

Other articles of this Issue 4/2016

Neurotherapeutics 4/2016 Go to the issue

Editorial

Stroke, Inflammation and the Immune Response: Dawn of a New Era

Review

Prophylactic Antibiotic Therapy for Preventing Poststroke Infection

Review

Clinical Trials of Immunomodulation in Ischemic Stroke

Review

Microglia and Monocyte-Derived Macrophages in Stroke

Original Article

CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study

Original Article

Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis